Lanean...
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
INTRODUCTION: Elevated expression of erbB3 rendered erbB2-overexpressing breast cancer cells resistant to paclitaxel via PI-3 K/Akt-dependent upregulation of Survivin. It is unclear whether an erbB3-targeted therapy may abrogate erbB2-mediated paclitaxel resistance in breast cancer. Here, we study t...
Gorde:
Egile Nagusiak: | , , , , , , , , , , |
---|---|
Formatua: | Artigo |
Hizkuntza: | Inglês |
Argitaratua: |
BioMed Central
2013
|
Gaiak: | |
Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3978722/ https://ncbi.nlm.nih.gov/pubmed/24168763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3563 |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|